Vericel (NASDAQ:VCEL) Shares Gap Down to $50.52

Vericel Co. (NASDAQ:VCEL)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $50.52, but opened at $46.00. Vericel shares last traded at $45.60, with a volume of 5,179 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Stephens boosted their price target on Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a research report on Friday. TD Cowen began coverage on Vericel in a report on Thursday, June 20th. They set a “buy” rating and a $55.00 target price on the stock. HC Wainwright lifted their price objective on shares of Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday. Truist Financial increased their target price on Vericel from $56.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Finally, BTIG Research lowered their price target on shares of Vericel from $56.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, July 15th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $54.50.

Vericel Trading Up 0.2 %

The business has a fifty day moving average price of $47.19 and a 200 day moving average price of $46.84.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $52.70 million during the quarter, compared to the consensus estimate of $52.59 million. Vericel had a return on equity of 0.35% and a net margin of 0.37%. The business’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.11) earnings per share. Research analysts expect that Vericel Co. will post 0.11 earnings per share for the current fiscal year.

Insider Activity at Vericel

In other news, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $44.12, for a total transaction of $772,100.00. Following the completion of the transaction, the chief executive officer now directly owns 220,752 shares in the company, valued at $9,739,578.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $44.12, for a total value of $772,100.00. Following the completion of the transaction, the chief executive officer now owns 220,752 shares of the company’s stock, valued at $9,739,578.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sean C. Flynn sold 6,772 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $45.02, for a total transaction of $304,875.44. Following the completion of the transaction, the insider now owns 487 shares of the company’s stock, valued at approximately $21,924.74. The disclosure for this sale can be found here. Insiders sold a total of 63,791 shares of company stock valued at $3,101,269 in the last quarter. Insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Vericel in the fourth quarter worth approximately $197,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Vericel in the 4th quarter valued at $33,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Vericel by 3.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,115 shares of the biotechnology company’s stock worth $930,000 after buying an additional 767 shares during the period. Conestoga Capital Advisors LLC raised its stake in Vericel by 4.9% during the fourth quarter. Conestoga Capital Advisors LLC now owns 2,339,960 shares of the biotechnology company’s stock worth $83,326,000 after buying an additional 109,215 shares during the last quarter. Finally, Louisiana State Employees Retirement System acquired a new position in Vericel in the fourth quarter valued at $851,000.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.